Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Iulianna Taritsa"'
Autor:
Cole V. Roblee, BS, Rebecca Arteaga, BA, Iulianna Taritsa, BS, Mona Ascha, MD, Joshua P. Weissman, BBA, Paige Hackenberger, MD, Megan Perez, MD, Marco Ellis, MD, Sumanas W. Jordan, MD, PhD
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 12, Iss 11, p e6297 (2024)
Background:. Nonbinary individuals assigned female at birth are increasingly presenting for gender-affirming chest surgery (GCS). However, little is known about psychosocial outcomes in this group. We compare patient-reported and clinical outcomes af
Externí odkaz:
https://doaj.org/article/14001b9472b346a8ae47be386136041a
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 11, Iss 10S, Pp 113-113 (2023)
Externí odkaz:
https://doaj.org/article/5d08f166b66247d0831e6c4a1a86774b
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 6:48-51
Here we discuss the dramatic cutaneous reactions of two patients receiving targeted therapies for cancer (one on a MEK inhibitor/BRAF inhibitor and the other receiving carfilzomib). Demodicosis was the underlying cause in both cases, though the infec
Autor:
Iulianna Taritsa, Eric Fossel
Publikováno v:
Iulianna Taritsa
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Michael J. Boctor, Julian L. Klosowiak, Simon Moradian, Iulianna Taritsa, Gregory A. Dumanian, Jason H. Ko
Publikováno v:
Neurosurgical Focus: Video. 8:V12
In the United States, an estimated 185,000 individuals undergo amputation of their upper or lower limb. This results in residual limb pain in up to 85% of cases. Targeted muscle reinnervation (TMR) is a technique that has been shown to prevent sympto
Publikováno v:
Cancer Research. 82:4244-4244
Lysosome-induced immunogenic cell death (LIICD) is a powerful mechanism of targeting cancer cells that kills circulating malignant cells and primes the host’s immune cells against future remission. Current immunotherapies for cancer are limited in